MultiCell Technologies Inc (MCET)

[TPX]

MCET NEWS! Fatigue Market Pipeline 2016 Global Therapeutics Review Report

Aug 25, 2016

PUNE, India, Aug 25, 2016 (PR Newswire Europe via COMTEX) -- PUNE, India, August 25, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Fatigue - Pipeline Review, H2 2016" market research report to its store providing an overview of the Fatigue's therapeutic pipeline with comprehensive information on the therapeutic development for Fatigue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects.

Fatigue also referred to as tiredness, exhaustion, lethargy, listlessness, and describes a physical and/or mental state of being tired and weak. Signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite. Complete report on H2 2016 pipeline review of Fatigue with 18 market data tables and 12 figures, spread across 55 pages is available at http://www.rnrmarketresearch.com/fatigue-pipeline-review-h2-2016-market-report.html .



Fatigue pipeline therapeutics constitutes close to 6 molecules which approximately 6 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 1, 3, 1 and 1 respectively. This research outlays comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects.

Companies discussed in this Fatigue Pipeline Review, H2 2016 report include BioLite, Inc., Biovista Inc., Grifols, S.A., Hemispherx Biopharma, Inc. and MultiCell Technologies, Inc. Drug Profiles discussed in this research are (lofepramine hydrochloride + phenylalanine), alpha-1 proteinase inhibitor (human), BLI-1402, Recombinant A1PI, rintatolimod and Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

The report also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Order a copy of fatigue pipeline 2016 market research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=662427 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Fatigue and reviews pipeline therapeutics for Fatigue by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Fatigue therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Fatigue therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Fatigue.

Another newly published market research report titled on Hidradenitis Suppurativa - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Cellceutix Corporation, Celtaxsys, Inc., Delenex Therapeutics AG, Johnson & Johnson, Novartis AG and Sandoz International GmbH. Hidradenitis Suppurativa Pipeline market research report of 63 pages is available at http://www.rnrmarketresearch.com/hidradenitis-suppurativa-pipeline-review-h2-2016-market-report.html .

Explore more reports on Mental Illness Drugs [http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/mental-illness-drugs ] .

http://www.marketwatch.com/story/fatigue-market-pipeline-2016-global-therapeutics-review-report-2016-08-25-6203110